Teduglutide (GLP-2 Drug) for Short Bowel Syndrome: From Gut Peptide Biology to Clinical Therapy
Teduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutrition dependence — a gut peptide drug for a devastating surgical condition.
Quick Facts
What This Study Found
Teduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutrition dependence — a gut peptide drug for a devastating surgical condition.
Key Numbers
How They Did This
research study.
Why This Research Matters
Relevant for peptide research.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
Trust & Context
- Key Stat:
- Key finding Teduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutriti
- Evidence Grade:
- emerging evidence.
- Study Age:
- Published in 2010.
- Original Title:
- Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
- Published In:
- Current opinion in molecular therapeutics, 12(6), 798-809 (2010)
- Authors:
- Yazbeck, Roger
- Database ID:
- RPEP-01714
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Teduglutide (GLP-2 Drug) for Short Bowel Syndrome: From Gut Peptide Biology to Clinical Therapy
What was found?
Teduglutide, a GLP-2 analog, demonstrated clinical benefit for short bowel syndrome by promoting intestinal adaptation and reducing parenteral nutrition dependence — a gut peptide drug for a devastating surgical condition.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01714APA
Yazbeck, Roger. (2010). Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.. Current opinion in molecular therapeutics, 12(6), 798-809.
MLA
Yazbeck, Roger. "Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.." Current opinion in molecular therapeutics, 2010.
RethinkPeptides
RethinkPeptides Research Database. "Teduglutide, a glucagon-like peptide-2 analog for the treatm..." RPEP-01714. Retrieved from https://rethinkpeptides.com/research/yazbeck-2010-teduglutide-a-glucagonlike-peptide2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.